Key milk nutrients, calcium and vitamin D, may do more than just help keep your bones strong. Increasing intake of calcium and vitamin D could reduce the risk for cancer in women by at least 60 percent, according to a new study published in the American Journal of Clinical Nutrition.
Taking folic acid supplements does not reduce the risk of developing precancerous tumors in the colon and may even increase the risk, a new study has found.
A drug described by some people as a “genius pill”for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as “chemo-brain,”according to a University of Rochester Medical Center study.
GlaxoSmithKline (GSK) announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC).
The synthetic form of a hormone previously found to produce a feeling of fullness when eating and reduce body weight, also may help curb binge eating and the desire to eat high-fat foods and sweets.
New research indicates that folic acid supplementation does not decrease the risk of benign colorectal tumors, but may possibly increase the risk for some types of colorectal tumors, according to a study in the June 6 issue of JAMA.
GlaxoSmithKline (GSK) today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC).
Otsuka Pharmaceutical Co, Ltd., and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority (six month review target) review the supplemental New Drug Application (sNDA) of the atypical antipsychotic ABILIFY? (aripiprazole) for the treatment of pediatric patients (13-17 years old) with schizophrenia.
In head-to-head trials of two drugs, the one deemed better appears to depend largely on who is funding the study, according to an analysis of nearly 200 statin-drug comparisons carried out between 1999 and 2005.
Nutrition 21, Inc. (NASDAQ: NXXI) announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome?, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).